ENDOCAN

ENDOCAN-1 will investigate if a future large scale, UK-wide trial to determine whether a cannabinoid can reduce endometriosis-associated pain is possible. 100 women with pelvic pain due to endometriosis will be randomly assigned to take MRX1 CBD drug candidate or identical placebo for 12 weeks.

Chief Investigator: Lucy Whitaker

Number and location of participating sites (by region/country): N/A

EudraCT number: N/A

ISRCTN number: N/A

Funder: Chief Scientists Office

 

Start and End date

Of grant award: 05 January 2024 - 31 October 2026

Of recruitment N/A

 

Current Status: In Set-Up     

 

UK GDPR privacy statement: UK GDPR statement provided at consent

 

ECTU Involvement:  Methodology & Statistics / Health Economics / Data Management & Programming

This article was published on